CD300ld on neutrophils is required for tumour-driven immune suppression In cancer, the immune system often gets suppressed, making it hard to treat. Scientists have found a molecule called CD300ld that is important for this suppression. When they blocked CD300ld in mice with tumors, it made the tumors shrink and improved the immune system’s ability to…
This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission. The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the…
This study tested a new treatment called mezigdomide, combined with dexamethasone, for people with multiple myeloma (a type of cancer). The treatment showed promise in patients who had already tried other treatments, including those resistant to lenalidomide and pomalidomide. In the first phase of the study, they tested the treatment on 77 patients to determine…
